DexCom (DXCM) to Release Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $1.2520 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $70.16 on Tuesday. The stock has a market cap of $27.36 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 1.25 and a beta of 1.49. DexCom has a 1 year low of $54.11 and a 1 year high of $93.25. The firm has a fifty day moving average price of $68.80 and a 200-day moving average price of $70.07. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DXCM shares. TD Cowen decreased their price target on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Evercore started coverage on DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target on the stock. JPMorgan Chase & Co. dropped their price target on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.00.

Insider Buying and Selling at DexCom

In other DexCom news, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the transaction, the director directly owned 35,088 shares of the company’s stock, valued at $2,071,946.40. This trade represents a 7.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.32% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently modified their holdings of DXCM. Vestal Point Capital LP purchased a new stake in DexCom during the 3rd quarter valued at $43,738,000. Dimensional Fund Advisors LP increased its position in DexCom by 52.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,444,566 shares of the medical device company’s stock valued at $97,187,000 after acquiring an additional 497,039 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of DexCom by 2,602.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 408,689 shares of the medical device company’s stock valued at $35,674,000 after acquiring an additional 393,568 shares during the period. Schonfeld Strategic Advisors LLC raised its stake in shares of DexCom by 953.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 364,700 shares of the medical device company’s stock valued at $24,541,000 after acquiring an additional 330,068 shares during the period. Finally, Polar Capital Holdings Plc bought a new stake in shares of DexCom in the 3rd quarter worth about $20,757,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.